NeuroMetrix, Inc. To Launch First FDA-Approved Medical Device for Fibromyalgia

 

Novel medical device and technology company, NeuroMetrix, Inc. (Nasdaq: NURO), will launch the first and only medical device authorized by the FDA to help reduce the symptoms of fibromyalgia.

The full commercial launch of the company’s Quell® Fibromyalgia device is expected to take place in Q2 2023. A Pathfinder Program will be launched on 1 December 2022 to validate and further refine the commercial process.

Highlights

  • 25 key opinion leaders in fibromyalgia practice across the United States will be involved in the company’s Pathfinder Program.
  • The Program will enable NeuroMetrix to clarify its messaging and distribution process to increase market access to its technology.
  • Quell Fibromyalgia is a wearable neuromodulator enabled by a proprietary microchip to provide precise, high-power nerve stimulation in a form factor the size of a credit card.
  • NeuroMetrix’s Quell technology is covered by 23 U.S. utility patents.

NeuroMetrix’s device is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. It can be used during sleep.

Share This Article

 

About the Author

NeuroMetrix, Inc. To Launch First FDA-Approved Medical Device for Fibromyalgia

Editor Prism MarketView